Switch to:
More From Other Websites
Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink Feb 24 2017
NASH Is Todd Hagopian's Top Biotech Sub-Sector For 2017 Feb 24 2017
Ten Stocks That Still Look Cheap Feb 24 2017
7 Ultra-Cheap Value Stocks to Buy Now Feb 24 2017
Gilead Sciences Expects a Fall in Its HCV Product Sales in 2017 Feb 24 2017
AbbVie Stronger Bet Than Gilead, Amgen — At Least Until 2020: Leerink Feb 23 2017
Gilead Sciences, Inc. (GILD) EPCLUSA Access To Be Provided In Ontario For Treatment Of Hepatitis C Feb 23 2017
Baby Boomers: Gilead’s New Hep C Target Group Feb 23 2017
This Strategy Could Boost GILD’s HIV Franchise Revenue in 2017 Feb 23 2017
These Regimens Are Expected to See Solid Global Demand in 2017 Feb 23 2017
Big Pharma Quietly Enlists Leading Professors to Justify $1,000-a-Day Drugs Feb 23 2017
Solid Uptake of This Drug Could Drive Gilead’s 2017 Product Sales Feb 23 2017
Cramer: Why Gilead could be a value trap Feb 22 2017
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017
Gilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs Feb 22 2017
Gilead Sciences Expects to Witness an Earnings Fall in 2017 Feb 22 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK